
A malaria vaccine price deal could protect up to one million more children.
The planned 40% price cut could save about $50 million over three years.
Every serving. No expiration date.

The planned 40% price cut could save about $50 million over three years.

The rule targets excessive distribution markups while requiring manufacturers to maintain supply.

A school-leaving law became rare causal evidence that social policy can shape brain health decades later.

A few strategically bare loops replaced a forest of compromises.

A more precise signal gave exhausted treatment paths one more opening.

A bridge for wildlife became a safety system for everyone.

The system reasoned through 304 difficult cases step by step, but the result is still a benchmark—not patient care.

Multiple coveys are an early sign that open-savanna restoration is rebuilding room for a long-declining bird.

One tumor. One recipe. A 42% lower relative risk.

A circuit map hints that plasticity and hallucination may not be inseparable.

One positron. Months of control. A new precision tool for fundamental physics.

Exercise kept the heart inside the Mars envelope.

In an ongoing trial, nearly three-quarters had not needed the usual treatments after a median of more than two years.

In trials, 24% met treatment-stopping criteria versus none on placebo; 19% stayed controlled 24 weeks after stopping all therapy.

The long pattern—not one day's reading—may help clinicians spot who needs earlier attention.

NASA's newly launched space telescope has cleared an early commissioning test with more optical precision than its requirement demanded.

Six hospitals changed everyday anesthesia practice, lowering estimated emissions and anesthetic spending without worsening tracked outcomes.

The first Afia Birago's puddle frogs ever born under human care are now hopping at London Zoo.

The study will test whether clearing amyloid, then adding a second mechanism, can delay inherited Alzheimer's.

Reported malaria deaths fell from 3,259 in 2011 to 52 in 2025.

An EMA committee recommended a once-daily oral RAS inhibitor for eligible adults with metastatic pancreatic cancer.

A randomized trial found continuous glucose monitoring added about five hours a day in the target range—even without insulin.

Eight complete responses. Twelve patients.

The future changed 2.2 million times.